Thomas Lines

FRS International LLC manufactures and markets beverages and nutritional supplements. Its products include healthy energy, protein, slim, and defense used by athletes and wellness experts. The company was founded by Bruce R. Shirey, Richard Lamb and Thomas Lines in 2004 and is headquartered in Boston, MA.

FRS International LLC manufactures and markets beverages and nutritional supplements. Its products include healthy energy, protein, slim, and defense used by athletes and wellness experts. The company was founded by Bruce R. Shirey, Richard Lamb and Thomas Lines in 2004 and is headquartered in Boston, MA.

FRS International LLC manufactures and markets beverages and nutritional supplements. Its products include healthy energy, protein, slim, and defense used by athletes and wellness experts. The company was founded by Bruce R. Shirey, Richard Lamb and Thomas Lines in 2004 and is headquartered in Boston, MA.

Quercis Pharma AG is a private biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is focused on developing a pipeline of late-stage clinical studies that aim to prevent venous thromboembolism (VTE) in cancer patients. The Swiss company's lead drug candidate acts as an antithrombotic with significantly lower risk of adverse events than existing treatments. Quercis Pharma also targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola, and COVID-19. The company is preparing to conduct a number of studies for the treatment of SCD (phase 2) and COVID-19 (phase 2/3). Quercis plans to initiate two phase 3 studies for the prevention of VTE in pancreatic cancer and glioblastoma patients and will pursue FDA approval for the prevention of VTE in all cancer types based on these studies. The company was founded in 2019 by Thomas Lines, who has been the CEO since then.

Quercis Pharma AG is a private biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is focused on developing a pipeline of late-stage clinical studies that aim to prevent venous thromboembolism (VTE) in cancer patients. The Swiss company's lead drug candidate acts as an antithrombotic with significantly lower risk of adverse events than existing treatments. Quercis Pharma also targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola, and COVID-19. The company is preparing to conduct a number of studies for the treatment of SCD (phase 2) and COVID-19 (phase 2/3). Quercis plans to initiate two phase 3 studies for the prevention of VTE in pancreatic cancer and glioblastoma patients and will pursue FDA approval for the prevention of VTE in all cancer types based on these studies. The company was founded in 2019 by Thomas Lines, who has been the CEO since then.